AmorChem invests in McGill ovarian cancer project
Canadian life sciences venture capital firm AmorChem has invested in a McGill University project focused on the identification of small molecules to treat an aggressive form of ovarian cancer.
Canadian life sciences venture capital firm AmorChem has invested in a McGill University project focused on the identification of small molecules to treat an aggressive form of ovarian cancer.
Copyright PEI Media
Not for publication, email or dissemination